Press Releases Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
4.62 ^USD	+5.48%		+4.05%	-14.76%

May. 16	Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating	MT
May. 15	Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024	May. 16	GL
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024	May. 16	AQ
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates	May. 15	GL
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates	May. 15	AQ
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024	May. 07	GL
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer	May. 06	GL
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024	Apr. 22	GL
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat	Mar. 27	GL
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat	Mar. 27	AQ
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors	Mar. 25	GL
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates	Mar. 25	GL
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences	Feb. 29	GL
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences	Feb. 29	AQ
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock	Jan. 25	GL
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock	Jan. 23	GL
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH	Jan. 22	GL
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic	Dec. 04	GL
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic	Dec. 04	AQ
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit	Nov. 28	GL
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit	Nov. 28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

Press Releases

Filters